An anonymous director reports

CARDIOL THERAPEUTICS TO WEBCAST VIRTUAL ANNUAL GENERAL MEETING OF SHAREHOLDERS ON JUNE 24TH AT 4:30 P.M. EDT

Cardiol Therapeutics Inc.'s virtual annual general meeting of shareholders will be webcast on June 24, 2026, at 4:30 p.m. EDT.

Cardiol Therapeutics' 2026 AGM

When:  June 24, 2026, at 4:30 p.m. EDT

Where:  virtual meeting only by live webcast on-line

Additional information about the AGM, including details on how to participate and vote, is available on the company's website.

About Cardiol Therapeutics Inc.

Cardiol Therapeutics is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The company's lead small-molecule drug candidate, CardiolRx, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis and heart failure.

The Maveric program is evaluating CardiolRx for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits and hospitalizations. The program comprises the completed phase II Maveric pilot study (NCT05494788) and the continuing pivotal phase III Maveric trial (NCT06708299). The U.S. FDA (Food and Drug Administration) has granted orphan drug designation to CardiolRx for the treatment of pericarditis, including recurrent pericarditis.

The Archer program also studied CardiolRx in acute myocarditis -- an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed phase II Archer study (NCT05180240), which evaluated the safety, tolerability and efficacy of CardiolRx in this patient population.

The company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure -- a leading cause of death and hospitalization in the developed world, with associated health care costs in the United States exceeding $30-billion (U.S.) per year.

We seek Safe Harbor.